PGC-1β regulates HER2-overexpressing breast cancer cells proliferation by metabolic and redox pathways
- 255 Downloads
Breast cancer is a prevalent neoplastic disease among women worldwide which treatments still present several side effects and resistance. Considering that cancer cells present derangements in their energetic homeostasis, and that peroxisome proliferator-activated receptor- gamma coactivator 1 (PGC-1) is crucial for cellular metabolism and redox signaling, the main objective of this study was to investigate whether there is a relationship between PGC-1 expression, the proliferation of breast cancer cells and the mechanisms involved. We initially assessed PGC-1β expression in complementary DNA (cDNA) from breast tumor of patients bearing luminal A, luminal B, and HER2-overexpressed and triple negative tumors. Our data showed that PGC-1β expression is increased in patients bearing HER2-overexpressing tumors as compared to others subtypes. Using quantitative PCR and immunoblotting, we showed that breast cancer cells with HER2-amplification (SKBR-3) have greater expression of PGC-1β as compared to a non-tumorous breast cell (MCF-10A) and higher proliferation rate. PGC-1β expression was knocked down with short interfering RNA in HER2-overexpressing cells, and cells decreased proliferation. In these PGC-1β-inhibited cells, we found increased citrate synthase activity and no marked changes in mitochondrial respiration. Glycolytic pathway was decreased, characterized by lower intracellular lactate levels. In addition, after PGC-1β knockdown, SKBR-3 cells showed increased reactive oxygen species production, no changes in antioxidant activity, and decreased expression of ERRα, a modulator of metabolism. In conclusion, we show an association of HER2-overexpression and PGC-1β. PGC-1β knockdown impairs HER2-overexpressing cells proliferation acting on ERRα signaling, metabolism, and redox balance.
KeywordsBreast cancer subtypes HER2- overexpressing PGC-1β Proliferation
The authors thank Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) for providing financial support.
Compliance with ethical standards
Conflicts of interest
- 1.World Health Organization. 2015 [http://www.who.int/topics/cancer/en]
- 2.Untch M, Gerber B, Harbeck N, Jackisch C, Marschner N, Möbus V, et al. 13th st. Gallen International Breast Cancer Conference 2013: primary therapy of early breast cancer evidence, controversies, consensus—opinion of a German team of experts (Zurich 2013). Breast Care (Basel). 2013;8(3):221–9. doi: 10.1159/000351692.Google Scholar
- 4.Victorino VJ, Pizzatti L, Michelletti P, Panis C. Oxidative stress, redox signaling and cancer chemoresistance: putting together the pieces of the puzzle. Curr Med Chem. 2014;21(28):3211–26.Google Scholar
- 8.Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal. 2012;16(11):1295–322. doi: 10.1089/ars.2011.4414.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Chausse B, Solon C, da Silva CC C, Masselli Dos Reis IG, Manchado-Gobatto FB, Gobatto CA, et al. Intermittent fasting induces hypothalamic modifications resulting in low feeding efficiency, low body mass and overeating. Endocrinology. 2014;155(7):2456–66. doi: 10.1210/en.2013-2057.CrossRefPubMedGoogle Scholar
- 19.Diers AR, Broniowska KA, Chang CF, BlakeHill R, Hogg N. S-nitrosation of monocarboxylate transporter 1: inhibition of pyruvate-fueled respiration and proliferation of breast cancer cells. Free Radical Biology and Medicine. 2014;69:229–38. doi: 10.1016/j.freeradbiomed.2014.01.031.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Deblois G, Hall JA, Perry MC, Laganière J, Ghahremani M, Park M, et al. Genome-wide identification of direct target genes implicates estrogen-related receptor alpha as a determinant of breast cancer heterogeneity. Cancer Res. 2009;69(15):6149–57. doi: 10.1158/0008-5472.CAN-09-1251.CrossRefPubMedGoogle Scholar